<div id="readability-page-1"><div><p>Guardant Health (GH) is back in focus after TRICARE agreed to cover its FDA approved Shield blood test for colorectal cancer screening for active duty U.S. military members and eligible families in Florida.</p> <p>See our latest analysis for Guardant Health.</p> <p>The TRICARE decision and recent revenue update sit against a strong run in the shares, with a 90 day share price return of 76.1% and a 1 year total shareholder return of 189.16%, suggesting momentum has been building despite a weaker 5 year total shareholder return of 30.84%.</p> <p>If Guardant Health has you rethinking the healthcare theme, this could be a good moment to size up other healthcare stocks that are catching investors' attention.</p> <p>With Guardant Health now trading near US$110 after a sharp run and analysts’ targets clustered around roughly US$120, plus an intrinsic value estimate at a larger discount, the real question is whether there is still a buying opportunity here or if the market is already pricing in future growth.</p> <h2>Most Popular Narrative: 6.8% Undervalued</h2> <p>The widely followed narrative sets fair value for Guardant Health at about US$118, a touch above the last close near US$110, framing today’s optimism in numbers.</p> <p><em>Substantial regulatory, reimbursement, and clinical validation milestones (including Shield's breakthrough device status, NCCN guideline inclusion, and ongoing pilot studies) are paving the way for further guideline adoption, expanded payer coverage, and commercial inflections in Shield/MCED and Reveal volumes, significantly increasing future revenue and earnings visibility.</em></p> <p>Read the complete narrative.</p> <p>Want to see how this story translates into the valuation gap? The narrative leans hard on rapid revenue scaling, margin shift and an aggressive future earnings multiple. Curious what combination of growth, profitability and discount rate has to line up for that to hold?</p> <p><strong>Result: Fair Value of $118.18 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, the story could shift quickly if high R&amp;D and cash burn lead to fresh equity raises, or if payer adoption for Shield and other tests underwhelms.</p> <p>Find out about the key risks to this Guardant Health narrative.</p> <h2>Another View: High Growth, Higher Expectations</h2> <p>Our DCF model presents a different perspective. On this view, Guardant Health at US$110.17 sits about 37.5% below an estimated fair value of roughly US$176.29, which suggests the shares may be undervalued if those long term cash flow assumptions prove accurate. Which storyline do you find more convincing?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9931ee85-f6ce-4e16-a029-7898a0ecf7dd/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9931ee85-f6ce-4e16-a029-7898a0ecf7dd/chart/dcf"/><figcaption>GH Discounted Cash Flow as at Jan 2026</figcaption></figure><h2> Build Your Own Guardant Health Narrative</h2> <p>If this view does not quite fit how you see Guardant Health, you can stress test the assumptions yourself in minutes and Do it your way.</p> <p>A great starting point for your Guardant Health research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.</p> <h2>Looking for more investment ideas?</h2> <p>If Guardant Health has sparked your interest, do not stop here. Use this momentum to actively search for other opportunities that could suit your portfolio.</p> <ul> <li>Spot potential value by scanning these 883 undervalued stocks based on cash flows that align with your price and quality expectations before others get there first.</li> <li>Ride major tech shifts by checking out these 28 AI penny stocks that tie artificial intelligence themes to real business models and financials.</li> <li>Boost your income focus by screening these 12 dividend stocks with yields &gt; 3% that combine yield with underlying business fundamentals you can actually assess.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

<p>Guardant Health (GH) has gained attention following TRICARE's decision to cover its Shield blood test for colorectal cancer screening for military members and families in Florida. The stock has seen a 90-day return of 76.1% and a 1-year return of 189.16%. Analysts suggest a fair value of $118, indicating the stock may be undervalued at its current price of around $110. However, risks include high R&D costs and potential underwhelming payer adoption. Investors are encouraged to explore other healthcare stocks and opportunities.</p>

Guardant Health (GH) Valuation Check After TRICARE Coverage Win For Shield Blood Test